Contributions
Abstract: P743
Type: Poster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Introduction: Current National Institute for Health and Care Excellence guidelines state that people with Multiple Sclerosis (MS) should have access to an MS specialist service. In addition, the Progressive MS Alliance has highlighted rehabilitation of people with progressive MS as a priority research area. To date, however, there has been no investigation into the level of access and use of clinical services by people with progressive MS.
Objective: To investigate access and use of clinical services and Disease Modifying Therapies (DMTs) by people with progressive MS in the United Kingdom and to make comparisons between Primary Progressive MS (PPMS) and Secondary Progressive MS (SPMS).
Methods: People with PPMS and SPMS were recruited via the UK MS register and answered an online survey between August and September 2015. Participants were asked about access and use of MS specialist and clinical services, historic and current DMT use. Demographics, Multiple Sclerosis Impact Scale (MSIS-29), and EQ-5D health questionnaire were supplied from routinely collected data on the UK MS register.
Results: 1298 people with progressive MS responded [mean age 59±8 years, mean Time Since Diagnosis (TSD) 16±9 years]. 37% had PPMS (n=486) and 63% SPMS (n=812). Mean EQ-5D index was 0.49±0.2 and MSIS-29 physical and psychological sub-scores were 56±12 and 20±6 respectively.
82% reported having access to an MS specialist service. Most commonly accessed services were MS specialist Doctor/Nurse (50%), General Practitioner (45%) and Physiotherapist (32%). 5% were currently taking DMTs (PPMS=20%, SPMS=80%) and 24% had previously taken DMTs (PPMS=12%, SPMS=88%).
There were statistically significant associations (p< 0.01) between access to MS specialist services and current use of DMTs (X2=6.97) and to historic DMT use (X2=9.32). Those with PPMS had a statistically significant higher EQ-5D index than those with SPMS (0.57 and 0.50 respectively) and lower MSIS-29 physical (55 and 58) and psychological sub-scores (19 and 20) but also had a shorter TSD (9 and 18 years) (all p< 0.01).
Conclusion: This was one of the largest studies to date investigating service access by people with progressive MS. This study has found that access and use of clinical services is high in the United Kingdom and access is associated with DMT use. In the sample those with PPMS had a shorter TSD, better quality of life and lower MSIS-29 scores than those with SPMS.
Disclosure:
Evan Campbell: nothing to disclose.
Lorna Paul: nothing to disclose.
Elaine Coulter: nothing to disclose.
Angus K McFadyen: nothing to disclose.
Linda Renfrew: nothing to disclose.
Paul Mattison: nothing to disclose.
Abstract: P743
Type: Poster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Introduction: Current National Institute for Health and Care Excellence guidelines state that people with Multiple Sclerosis (MS) should have access to an MS specialist service. In addition, the Progressive MS Alliance has highlighted rehabilitation of people with progressive MS as a priority research area. To date, however, there has been no investigation into the level of access and use of clinical services by people with progressive MS.
Objective: To investigate access and use of clinical services and Disease Modifying Therapies (DMTs) by people with progressive MS in the United Kingdom and to make comparisons between Primary Progressive MS (PPMS) and Secondary Progressive MS (SPMS).
Methods: People with PPMS and SPMS were recruited via the UK MS register and answered an online survey between August and September 2015. Participants were asked about access and use of MS specialist and clinical services, historic and current DMT use. Demographics, Multiple Sclerosis Impact Scale (MSIS-29), and EQ-5D health questionnaire were supplied from routinely collected data on the UK MS register.
Results: 1298 people with progressive MS responded [mean age 59±8 years, mean Time Since Diagnosis (TSD) 16±9 years]. 37% had PPMS (n=486) and 63% SPMS (n=812). Mean EQ-5D index was 0.49±0.2 and MSIS-29 physical and psychological sub-scores were 56±12 and 20±6 respectively.
82% reported having access to an MS specialist service. Most commonly accessed services were MS specialist Doctor/Nurse (50%), General Practitioner (45%) and Physiotherapist (32%). 5% were currently taking DMTs (PPMS=20%, SPMS=80%) and 24% had previously taken DMTs (PPMS=12%, SPMS=88%).
There were statistically significant associations (p< 0.01) between access to MS specialist services and current use of DMTs (X2=6.97) and to historic DMT use (X2=9.32). Those with PPMS had a statistically significant higher EQ-5D index than those with SPMS (0.57 and 0.50 respectively) and lower MSIS-29 physical (55 and 58) and psychological sub-scores (19 and 20) but also had a shorter TSD (9 and 18 years) (all p< 0.01).
Conclusion: This was one of the largest studies to date investigating service access by people with progressive MS. This study has found that access and use of clinical services is high in the United Kingdom and access is associated with DMT use. In the sample those with PPMS had a shorter TSD, better quality of life and lower MSIS-29 scores than those with SPMS.
Disclosure:
Evan Campbell: nothing to disclose.
Lorna Paul: nothing to disclose.
Elaine Coulter: nothing to disclose.
Angus K McFadyen: nothing to disclose.
Linda Renfrew: nothing to disclose.
Paul Mattison: nothing to disclose.